These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15516341)

  • 1. Determination of selectivity and efficacy of fatty acid synthesis inhibitors.
    Kodali S; Galgoci A; Young K; Painter R; Silver LL; Herath KB; Singh SB; Cully D; Barrett JF; Schmatz D; Wang J
    J Biol Chem; 2005 Jan; 280(2):1669-77. PubMed ID: 15516341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (p)ppGpp/GTP and Malonyl-CoA Modulate Staphylococcus aureus Adaptation to FASII Antibiotics and Provide a Basis for Synergistic Bi-Therapy.
    Pathania A; Anba-Mondoloni J; Gominet M; Halpern D; Dairou J; Dupont L; Lamberet G; Trieu-Cuot P; Gloux K; Gruss A
    mBio; 2021 Feb; 12(1):. PubMed ID: 33531402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy.
    Ondeyka JG; Zink DL; Young K; Painter R; Kodali S; Galgoci A; Collado J; Tormo JR; Basilio A; Vicente F; Wang J; Singh SB
    J Nat Prod; 2006 Mar; 69(3):377-80. PubMed ID: 16562839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity.
    Freiberg C; Brunner NA; Schiffer G; Lampe T; Pohlmann J; Brands M; Raabe M; Häbich D; Ziegelbauer K
    J Biol Chem; 2004 Jun; 279(25):26066-73. PubMed ID: 15066985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.
    Wang Y; Ma S
    ChemMedChem; 2013 Oct; 8(10):1589-608. PubMed ID: 23894064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens.
    Brinster S; Lamberet G; Staels B; Trieu-Cuot P; Gruss A; Poyart C
    Nature; 2009 Mar; 458(7234):83-6. PubMed ID: 19262672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of antibacterial activity and minimum inhibitory concentration of larval extract of fly via resazurin-based turbidometric assay.
    Teh CH; Nazni WA; Nurulhusna AH; Norazah A; Lee HL
    BMC Microbiol; 2017 Feb; 17(1):36. PubMed ID: 28209130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staphylococcus aureus Utilizes Host-Derived Lipoprotein Particles as Sources of Fatty Acids.
    Delekta PC; Shook JC; Lydic TA; Mulks MH; Hammer ND
    J Bacteriol; 2018 Jun; 200(11):. PubMed ID: 29581406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.
    Yao J; Rock CO
    J Biol Chem; 2015 Mar; 290(10):5940-6. PubMed ID: 25648887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus.
    Gloux K; Guillemet M; Soler C; Morvan C; Halpern D; Pourcel C; Vu Thien H; Lamberet G; Gruss A
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents.
    Herath KB; Jayasuriya H; Guan Z; Schulman M; Ruby C; Sharma N; MacNaul K; Menke JG; Kodali S; Galgoci A; Wang J; Singh SB
    J Nat Prod; 2005 Sep; 68(9):1437-40. PubMed ID: 16180833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials.
    Morvan C; Halpern D; Kénanian G; Hays C; Anba-Mondoloni J; Brinster S; Kennedy S; Trieu-Cuot P; Poyart C; Lamberet G; Gloux K; Gruss A
    Nat Commun; 2016 Oct; 7():12944. PubMed ID: 27703138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of FabH/FabF inhibitors from natural products.
    Young K; Jayasuriya H; Ondeyka JG; Herath K; Zhang C; Kodali S; Galgoci A; Painter R; Brown-Driver V; Yamamoto R; Silver LL; Zheng Y; Ventura JI; Sigmund J; Ha S; Basilio A; Vicente F; Tormo JR; Pelaez F; Youngman P; Cully D; Barrett JF; Schmatz D; Singh SB; Wang J
    Antimicrob Agents Chemother; 2006 Feb; 50(2):519-26. PubMed ID: 16436705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of bacterial fatty acid synthase type II inhibitors using a novel cellular bioluminescent reporter assay.
    Wallace J; Bowlin NO; Mills DM; Saenkham P; Kwasny SM; Opperman TJ; Williams JD; Rock CO; Bowlin TL; Moir DT
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5775-87. PubMed ID: 26169404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Staphylococcus aureus FASII bypass escape route from FASII inhibitors.
    Morvan C; Halpern D; Kénanian G; Pathania A; Anba-Mondoloni J; Lamberet G; Gruss A; Gloux K
    Biochimie; 2017 Oct; 141():40-46. PubMed ID: 28728970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery.
    Campbell JW; Cronan JE
    Annu Rev Microbiol; 2001; 55():305-32. PubMed ID: 11544358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.
    Parsons JB; Frank MW; Subramanian C; Saenkham P; Rock CO
    Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15378-83. PubMed ID: 21876172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis.
    Kwon YJ; Kim HJ; Kim WG
    Biol Pharm Bull; 2015; 38(5):715-21. PubMed ID: 25947917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous fatty acid metabolism in bacteria.
    Yao J; Rock CO
    Biochimie; 2017 Oct; 141():30-39. PubMed ID: 28668270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.